Rhode Island
House Bill Targets Pay-for-Delay Deals Under the Protecting Consumer Access to Generic Drugs Act
Content Files PDF XML TEXT Metadata download Descriptive Metadata (MODS) Preservation Metadata (PREMIS) All Content and Metadata files, including granules ZIP
Last updated:
Key points
- Representative Seth Magaziner introduced H.R. 10887 to prohibit pay-for-delay agreements between drug manufacturers.
- The bill seeks to accelerate generic and biosimilar competition to lower prescription costs for consumers.
- House leaders referred the bill to the Energy and Commerce and Judiciary committees on October 22, 2026.
NewsWK — Federal lawmakers are reviewing pay for delay drug legislation targeting financial agreements between major pharmaceutical companies and lower-cost generic makers. Representative Seth Magaziner, a Democrat from Rhode Island, introduced the bill during the second session of the 119th Congress on October 22, 2026. The legislation aims to restrict anti-competitive industry settlements.
How Would HR 10887 Impact Pay for Delay Deals in Medicine?
The proposed legislation, officially designated as HR 10887, directly bans brand-name pharmaceutical companies from paying generic producers to withhold cheaper alternatives from market shelves. Furthermore, the measure applies matching restrictions to biological product developers and biosimilar manufacturers. Consequently, federal lawmakers seek to prevent pharmaceutical firms from extending market exclusivity through financial compensation.
What Are the Core Goals of the Seth Magaziner Drug Bill?
The Seth Magaziner drug bill focuses on dismantling pay-for-delay agreements that block cheaper medicine options. Under the proposal, brand manufacturers cannot offer financial settlements to delay biosimilar or generic product entries. Therefore, the measure reinforces free-market competition to ensure timely consumer access to lower-cost pharmaceutical treatments.
What Does the Generic Drug Cost Legislation Change for Healthcare Consumers?
This generic drug cost legislation aims to lower healthcare expenses for American families by speeding up generic competition. However, prohibiting these payments ensures generic treatments enter retail pharmacies without unnecessary artificial delays. Thus, patients gain prompt access to cost-effective prescriptions.
Where Does the Legislation Stand in Congress?
On October 22, 2026, House leaders formally referred the bill to two separate congressional panels. Specifically, the legislation rests with the House Committee on Energy and Commerce alongside the House Committee on the Judiciary. In addition, the measure references multiple federal statutes, including provisions in Title 15 and Title 21 of the United States Code, plus Public Law 111-148.
This article was produced with the assistance of AI and reviewed by our editorial team.
Sources
Related: House Resolution 1499 Clears Way for Critical Votes on Mining, Higher Education, and Maritime Rules
Related: Study Examines Women on Parole Mental Health and Reentry Crises Across the US
See a typo? Report it here.
